Literature DB >> 33070318

Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing.

Leonardo I Green1, Christopher S Mathews1, Jo Waller1, Henry Kitchener2, Matejka Rebolj1.   

Abstract

Attendance at early recall and colposcopy is crucial to attaining the benefits of primary high-risk human papillomavirus (HR-HPV)-based screening. Within the English HPV pilot, we analysed deprivation- and age-related patterns of attendance at colposcopy and 12- and 24-month early recall of HR-HPV positive women screened in 2013 to 2015 (N = 36 466). We fitted logistic regression models for adjusted odds ratios (OR). Despite high overall attendance, area deprivation had a small but significant impact at both early recalls, for example, attendance at 24 months was 86.3% and 83.0% in less vs more deprived areas, respectively (ORadj : 0.76; 95% CI: 0.67-0.87). Older women (≥30 years) were more likely to attend early recall than younger women (<30 years), for example, attendance at 24 months was 86.1% vs 82.3%, respectively (ORadj : 1.32, 95% CI: 1.16-1.51). Most women attended colposcopy following a baseline referral, with 96.9% attendance among more deprived and 97.8% among less deprived areas (ORadj : 0.70; 95% CI: 0.55-0.88). Differences in colposcopy attendance by deprivation level at 12 and 24 months were of approximately the same magnitude. In conclusion, attendance at early recall and colposcopy was reassuringly high. Although there were statistically significant differences by deprivation and age group, these were small in absolute terms.
© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.

Entities:  

Keywords:  attendance; cervical cancer screening; colposcopy; early recall; human papillomavirus

Mesh:

Year:  2020        PMID: 33070318     DOI: 10.1002/ijc.33348

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Colposcopy non-attendance following an abnormal cervical cancer screening result: a prospective population-based cohort study.

Authors:  Linda A Liang; Sylke R Zeissig; Gunther Schauberger; Sophie Merzweiler; Kathrin Radde; Sabine Fischbeck; Hans Ikenberg; Maria Blettner; Stefanie J Klug
Journal:  BMC Womens Health       Date:  2022-07-09       Impact factor: 2.742

2.  Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.

Authors:  Matejka Rebolj; Kate Cuschieri; Christopher S Mathews; Francesca Pesola; Karin Denton; Henry Kitchener
Journal:  BMJ       Date:  2022-05-31

3.  Adherence to follow-up after the exit cervical cancer screening test at age 60-64: A nationwide register-based study.

Authors:  Susanne F Jørgensen; Berit Andersen; Lone Kjeld Petersen; Matejka Rebolj; Sisse H Njor
Journal:  Cancer Med       Date:  2021-11-12       Impact factor: 4.452

4.  The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot.

Authors:  Francesca Pesola; Christopher Mathews; Matejka Rebolj; David Mesher; Kate Soldan; Henry Kitchener
Journal:  Br J Cancer       Date:  2022-03-26       Impact factor: 9.075

5.  Cytology interpretation after a change to HPV testing in primary cervical screening: Observational study from the English pilot.

Authors:  Matejka Rebolj; Christopher S Mathews; Karin Denton
Journal:  Cancer Cytopathol       Date:  2022-04-04       Impact factor: 4.264

6.  Awareness regarding and vaccines acceptability of human papillomavirus among parents of middle school students in Zunyi, Southwest China.

Authors:  Yan Xie; Li-Yu Su; Feng Wang; Hai-Yan Tang; Qiu-Ge Yang; Yi Jun Liu
Journal:  Hum Vaccin Immunother       Date:  2021-07-29       Impact factor: 4.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.